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Receptor tyrosine kinase signaling is critical for
mammalian craniofacial development, but the key
downstream transcriptional effectors remain un-
known. We demonstrate that serum response factor
(SRF) is induced by both platelet-derived growth fac-
tor (PDGF) and fibroblast growth factor (FGF)
signaling in mouse embryonic palatal mesenchyme
cells and that Srf neural crest conditional mutants
exhibit facial clefting accompanied by proliferation
and migration defects. Srf and Pdgfra mutants
interact genetically in craniofacial development, but
Srf and Fgfr1 mutants do not. This signal specificity
is recapitulated at the level of cofactor activation:
while both PDGF and FGF target gene promoters
show enriched genome-wide overlap with SRF ChIP-
seq peaks, PDGF selectively activates a network of
MRTF-dependent cytoskeletal genes. Collectively,
our results identify a role for SRF in proliferation
and migration during craniofacial development and
delineate a mechanism of receptor tyrosine kinase
specificity mediated through differential cofactor
usage, leading to a PDGF-responsive SRF-driven
transcriptional program in the midface.
INTRODUCTION
Receptor tyrosine kinases (RTKs) engage shared signaling
effectors, such as extracellular signal-related kinase (ERK) and
phosphatidylinositol 3-kinase (PI3K), but the in vivo phenotypes
associated with different RTK mutants can be quite distinct
(Lemmon and Schlessinger, 2010). A central question revolves
around how signal specificity arises from a seemingly general
set of transduction pathways. At a transcriptional level, RTK
signaling classically modulates the expression of immediate
early genes (IEGs) (Cochran et al., 1984; Lau and Nathans,
1987). While different RTK pathways, such as platelet-derived
growth factor (PDGF) and fibroblast growth factor (FGF)
signaling, induce similar sets of IEGs in cultured cells (Fam-
brough et al., 1999), genetic experiments in mice suggest a de-
gree of IEG specificity downstream of PDGF signaling (Schmahl
et al., 2007). Thus, a major goal remains to characterize the key332 Developmental Cell 31, 332–344, November 10, 2014 ª2014 Elstranscriptional mediators regulated by RTK signaling and deter-
mine their specificity downstream of different receptors.
Development of the mammalian face comprises derivatives
from all three germ layers, including a unique contribution from
the neural crest. Many components of RTK signaling are linked
to craniofacial syndromes and phenotypes in both mice and
humans (Newbern et al., 2008; Bentires-Alj et al., 2006). Mice
harboring neural crest cell (NCC) conditional loss of PDGF re-
ceptor a (PDGFRa) using the Wnt1-Cre transgene exhibit cleft
face and palate (Tallquist and Soriano, 2003). Combined loss
of both PDGFRa-specific ligands, PDGFA and PDGFC, results
in facial clefting (Ding et al., 2004). In humans, mutations in and
around PDGFC (Choi et al., 2009; Calcia et al., 2013) and
PDGFRa (Rattanasopha et al., 2012) have been associated
with cleft lip and palate, reflecting a conserved role for PDGF
signaling in mammalian midface development. It is interesting
that NCC conditional loss of FGF receptor 1 (FGFR1) also results
in craniofacial defects (Trokovic et al., 2003; Wang et al., 2013),
indicating a requirement for both PDGF and FGF signaling in
NCCs for craniofacial morphogenesis.
Serum response factor (SRF) is a transcription factor critical
for coupling actin dynamics and signaling pathways to gene
expression (Posern and Treisman, 2006; Olson and Nordheim,
2010). SRF was identified as a regulator of the serum response
in fibroblasts (Treisman, 1987), and more recent work has
focused on understanding the mechanisms of SRF specificity
at the transcriptional level (Gineitis and Treisman, 2001), partic-
ularly in regard to interactions with its two major cofactor
families: ternary complex factors (TCFs) and myocardin-related
transcription factors (MRTFs) (Esnault et al., 2014). SRF can be
activated in response to many extracellular stimuli, including
PDGF and FGF (Treisman, 1996; Wang et al., 2004). However,
the specificity of SRF activation at a receptor level is unclear,
and a direct comparison of SRF function downstream of multiple
RTKs has not been carried out.
SRF is essential across many developmental and physiolog-
ical contexts, including mesoderm formation (Arsenian et al.,
1998), cardiac development (Parlakian et al., 2004), angiogen-
esis (Franco et al., 2008), oligodendrocyte differentiation (Stritt
et al., 2009), neuronal migration (Alberti et al., 2005), and circa-
dian regulation (Gerber et al., 2013). SRF was first implicated in
neural crest development through an in situ hybridization screen
(Adams et al., 2008), and neural crest conditional Srf mouse
mutants show defects in dorsal root ganglion (DRG) formation
(Wickramasinghe et al., 2008), cardiac outflow tract develop-
ment, and mandible formation (Newbern et al., 2008). No facialevier Inc.
Figure 1. SRF Is a Target of PDGF Signaling
in Craniofacial Development
(A and B) In E13.5 MEPMs, PDGF stimulation
increases (A) Srf mRNA (2-fold peak induction)
and (B) protein (7-fold peak induction) (n = 3). Data
plotted as mean ± SEM. *p < 0.05.
(C) SRF induction following PDGF stimulation re-
quires ERK, PI3K, andMRTF activity, as evidenced
by inhibition of these pathways. Cells treated with
30 ng/ml PDGFAA for desired duration. PD,
PD325901; LY, LY294002; LB, latrunculin B; CD,
cytochalasin D.
(D) At E11.5, Pdgfra and Srf mRNA are coex-
pressed in the developing MNP and less robustly
in the LNP.
See also Figure S1 and Table S2.
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SRF and RTK Signaling in Craniofacial Developmentclefting phenotypes have been previously reported, and the role
of SRF in midface development remains unknown.
In the present study, we report that SRF is required for cranio-
facial development and responds differentially to PDGF and
FGF signaling through selective interactions with MRTF and
TCF cofactors. Wnt1-Cre; Srffl/fl mutants exhibit overt facial
clefting as well as proliferation and migration deficits in the
cranial neural crest and its derivatives. We find that Srf and
Pdgfra double mutants (Wnt1-Cre; Srf+/fl; Pdgfra+/fl) display
varying degrees of craniofacial defects, but Srf and Fgfr1
(Wnt1-Cre; Srf+/fl; Fgfr1+/fl) do not interact genetically, indicating
that SRF function downstream of these two RTKs is not identical.
We demonstrate that this specificity is encoded at the level of
MRTF-SRF activation and recapitulated in the genome-wide
binding profile of SRF and MRTF at the promoters of PDGF
target genes, particularly those involved in cytoskeletal organi-
zation. Taken together, our studies illustrate a role for SRF in
controlling proliferation and migration during craniofacial devel-
opment and uncover an example of RTK specificity mediated
by a common transcription factor through differential cofactor
usage and unique output gene expression signatures.
RESULTS
PDGF Activates SRF in MEPMs, and PDGFRa and SRF
Are Coexpressed during Craniofacial Development
To identify transcriptional targets of PDGF signaling in the mid-
face, we carried out RNA sequencing (RNA-seq) in embryonic
day (E)13.5 mouse embryonic palatal mesenchyme (MEPM) cells
treated with PDGFA (which specifically activates PDGFRa), iden-
tifyingSrf as a PDGF target gene (Table S2 available online; Gene
Expression Omnibus [GEO] accession number GSE61755).
MEPMs express many palatal mesenchyme markers, including
Pdgfra, and have been used to study PDGF (Fantauzzo and Sor-Developmental Cell 31, 332–344, Niano, 2014) and Ephrin signaling (Bush
and Soriano, 2010). A quantitative PCR
(qPCR) time course revealed the peak of
Srf mRNA induction to occur at 60 min
following PDGF treatment (Figure 1A),
and western blot confirmed this increase
at the protein level (Figure 1B). The in-
crease in SRF protein prior to Srf mRNAis likely due in part to post-transcriptional regulation of IEG induc-
tion (Avraham and Yarden, 2011). We observed the appearance
of a shifted band following PDGF treatment; indeed, SRF is
phosphorylated at multiple residues in response to growth factor
treatment, andpreviouswork has shown that thesemodifications
canaffect SRFactivity in vitro (Rivera et al., 1993; Iyer et al., 2006).
Thus, we treated PDGF-stimulatedMEPM lysates with calf intes-
tinal phosphatase, which resulted in loss of the upper band (Fig-
ure S1A), indicating that PDGF treatment promotes SRF phos-
phorylation. To determine the signaling dependence of SRF
induction, we performedwestern blots following PDGF treatment
in the presence of PD325901 (MEK inhibitor), LY294002 (PI3K in-
hibitor), latrunculin B (MRTF inhibitor), and cytochalasin D (MRTF
activator). We found that PDGF-mediated SRF induction requires
both PI3K and ERK signaling aswell asMRTF activity (Figure 1C).
Next, we analyzed the expression pattern of Srf and Pdgfra
during craniofacial development. Whole-mount in situ hybridiza-
tion (WISH) revealed that both genes are expressed in the E11.5
medial nasal process (MNP) (Figure 1D), and we confirmed pro-
tein coexpression in the developing MNP and maxillary process
(MxP) with anti-SRF immunofluorescence on Pdgfra+/GFP re-
porter embryos (Hamilton et al., 2003) (Figure S1B). At E13.5,
both Srf and Pdgfra were present broadly in the craniofacial
region, with expression noted in the anterior palate at both the
mRNA and protein levels (Figures S1C and S1D). These experi-
ments show that PDGF induces SRF in an ERK-, PI3K-, and
MRTF-dependent manner and that SRF is coexpressed with
PDGFRa in the midface.
Srf Conditional Mutants Exhibit Overt Facial Clefting
and Interact Genetically with Pdgfra Mutants
but Not Fgfr1 Mutants
While cardiac, neuronal, and mandibular defects have been
observed in NCC conditional Srf mutants (Newbern et al.,ovember 10, 2014 ª2014 Elsevier Inc. 333
Figure 2. Wnt1-Cre; Srffl/fl Mutants Exhibit
Facial Clefting and Interact Genetically
with Pdgfra
(A–B’’’) NCC conditional deletion of Srf results in
fully penetrant facial clefting at both (A’) E11.5 and
(B’) E13.5. (A’’ and B’’) Embryos heterozygous for
both Srf and Pdgfra display a partially penetrant
clefting phenotype while (A’’’and B’’’) Srf homo-
zygous mutants missing one copy of Pdgfra
display exacerbated phenotypes, including severe
midline hemorrhage and blebbing.
(C) Frontal sections in E11.5 embryos show cleft-
ing and forebrain expansion in both theWnt1-Cre;
Srffl/fl and Wnt1-Cre; Srf+/fl; Pdgfra+/fl mutants as
well as midline hemorrhage in the double hetero-
zygous condition.
(D) Morphometry reveals differences in the dis-
tance between nasal pits and (D’) MxP length in
Wnt1-Cre; Srffl/fl mutants (n = 5 at E10.5, n = 11 at
E11.5) and Wnt1-Cre; Srf+/fl; Pdgfra+/fl embryos
(n = 4 at E10.5, n = 9 at E11.5) compared to con-
trols (n = 10 at E10.5, n = 10 at E11.5). *p < 0.05;
**p < 0.01. Scale bars, 200 mm. All data plotted as
mean ± SEM.
See also Figure S2 and Table S1.
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SRF and RTK Signaling in Craniofacial Development2008; Wickramasinghe et al., 2008), detailed analysis of the
craniofacial phenotypes in these mice has not been carried
out. Therefore, we conditionally disrupted Srf in NCCs using
theWnt1-Cre driver (Danielian et al., 1998). We found fully pene-
trant facial clefting in Wnt1-Cre; Srffl/fl mutants compared to
heterozygous Wnt1-Cre; Srf+/fl controls, which appear grossly
normal (Figures 2A–2B’). Furthermore,Wnt1-Cre; Srf+/fl; Pdgfra+/fl
double heterozygotes exhibit partially penetrant facial clefting
(Figures 2A’’ and 2B’’), and infrequently recovered Wnt1-Cre;
Srffl/fl; Pdgfra+/fl mutant embryos display even more severe phe-
notypes, characterized by gross midline hemorrhage and blis-
tering in the cephalic region (Figures 2A’’’ and 2B’’’) (Table S1).
The defects observed in Pdgfra/Srf double mutants are reminis-
cent of Pdgfra/ knockouts, which also exhibit facial clefting,
hemorrhaging, and blisters (Soriano, 1997). We next performed
hematoxylin and eosin staining, confirming that the facial
clefting extends through the midline in both Wnt1-Cre; Srffl/fl
and Wnt1-Cre; Srf+/fl; Pdgfra+/fl mutants at E11.5 (Figure 2C).
We carried out morphometric analysis to quantify the relative
severity of clefting across genotypes. We found significantly
increased distances between the nasal pits (Figure 2D), as well
as reduced MxP length (Figure 2D’), in Srf mutants beginning
as early as E10.5. No differences in mandibular morphogenesis
were detected at these stages (data not shown). Thus, SRF
function is required in NCCs for craniofacial development,
and Srf/Pdgfra double heterozygotes exhibit phenotypes despite
the grossly normal appearance of Srf or Pdgfra heterozygotes,
suggesting that these two genes may function within a common
network.
Given the activation of SRF in response to many extracellular
signals (including FGF), we hypothesized that SRF may also
function downstream of FGF signaling during craniofacial devel-334 Developmental Cell 31, 332–344, November 10, 2014 ª2014 Elsopment. Indeed, FGF stimulation induces Srf mRNA in E13.5
MEPMs; however, in contrast to PDGF signaling, FGF-mediated
SRF induction required ERK signaling but not PI3K or MRTF
activity (Figures S2A and S2B). Furthermore, no interaction
between Fgfr1 and Srf conditional mutants (Wnt1-Cre; Srf+/fl;
Fgfr1+/fl) was observed (Figure S2C), despite the fact that
FGFR1 is the primary FGF receptor in the neural crest and
craniofacial mesenchyme (Trokovic et al., 2003, Park et al.,
2008). These results suggest that activation of SRF by PDGF
and FGF signaling is fundamentally different and, more broadly,
that these two receptors perform at least a subset of nonoverlap-
ping functions.
We recently showed that the originalWnt1-Cre results in Wnt1
overexpression and enlargement of the midbrain and, therefore,
generated aWnt1-Cre2 transgenic line as an alternative without
these caveats (Lewis et al., 2013). Facial clefting phenotypes
obtained with this Cre driver were similar to those observed
with the original Wnt1-Cre (Figure S3A).
SRF Mutants Display Cell Proliferation and Migration
Deficits during Craniofacial Development
SRF is known to control a diverse range of cellular outcomes,
including cell proliferation, migration, survival, and differentia-
tion. Thus, we examined each of these processes in Wnt1-Cre;
Srffl/fl mutants to determine the basis for the observed clefting
phenotypes. We found reduced proliferation in the MNP of Srf
mutants (Figures 3A–3B’’) at both E10.5 and E11.5. Similarly,
we found fewer cells specifically in the MNP of E11.5 Wnt1-
Cre; Srffl/flmutant embryos (Figure 3C), although no such reduc-
tion in total cell number was observed at E10.5 (data not shown).
This spatiotemporally specific proliferation defect in Wnt1-Cre;
Srffl/fl mutants is consistent with previous work showing thatevier Inc.
Figure 3. Wnt1-Cre; Srffl/fl Mutants Display
Proliferation and Lineage Tracing Defects
In Vivo
(A–B’’) Here, (A and B) Srf mutants exhibit
decreased proliferation specifically in the MNP
at (A and A’’) E10.5 (n = 5) and (B and B’’) E11.5
(n = 7). **p < 0.001.
(C) The MNP of Srf conditional mutants is hypo-
cellular, with significantly fewer cells at E11.5
(n = 7). Cell counts were normalized to number of
cells in littermate control. *p < 0.005.
(D–E’) Here, (D and E) lineage tracing using the
ROSA26 reporter (R26R) reveals reduced contri-
bution of NCCs to (D and D’) the first and second
branchial arches (BA1, BA2) and (E and E’) FNP
at E9.5 (somite number indicated). Blue (lacZ
positive) cells are generated by Wnt1Cre-medi-
ated recombination and thus label the neural crest
and its derivatives.
Scale bars, 100mm.All dataplotted asmean±SEM.
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ation (He and Soriano, 2013). We did not find any difference
in apoptosis between control and Srf mutant embryos in the
MNP or lateral nasal process (LNP), and we did not detect any
change in the expression of MNP marker genes such as Alx3
(data not shown).
Classic studies have shown that many craniofacial structures
are predominantly derived from the neural crest (Couly et al.,
1993; Chai et al., 2000). To visualize defects in migration and
population of the craniofacial mesenchyme by NCCs, we
crossed Srf conditional mutants to R26R-lacZ mice (Soriano,
1999). At E9.5, Wnt1-Cre; Srffl/fl; R26R+/ mutant embryos
showed impaired neural crest contribution to the frontonasal
prominence (FNP), first branchial arch (BA1), and second bran-
chial arch (BA2) (Figures 3D and 3E). We often observed BA1
and BA2 defects in early E9.5 embryos (<18 somites, seven of
nine mutant embryos with phenotype) and FNP and BA2 defects
in late E9.5 embryos (R18 somites, six of nine mutant embryos
with phenotype). The combination of lineage tracing and pro-
liferation defects reflects the requirement of SRF activity in the
neural crest to both fully populate the craniofacial mesenchyme
and respond to proliferative signals.
SRF Is Required for Cellular Responses to RTK
Signaling in FPCs
SinceWnt1-Cre; Srffl/fl embryos are recovered below Mendelian
ratios at E13.5, we turned to an earlier stage of craniofacial
development to further investigate SRF function. Given the
in vivo defects observed in the E11.5 midface, we established
facial prominence cells (FPCs) from E11.5 embryos as a primary
cell culture model to study the effects of SRF loss; control
FPCs show robust expression of Srf, Pdgfra, and Fgfr1, and
Wnt1-Cre2; Srffl/fl mutant FPCs express almost no Srf mRNA
(Figure S3B) or protein (Figure S3C).
SRF is critical for maintaining proper cytoskeletal morphology
(Schratt et al., 2002). Thus, we stained Srf mutant FPCs for
F-actin and b-tubulin and observed gross defects in actin stressDevelopmefiber formation and microtubule organization (Figure 4A). Next,
we tested the proliferative response of FPCs to PDGF and FGF
stimulation. Surprisingly, only PDGF induced proliferation in
control FPCs, while Srf mutant FPCs fail to proliferate following
PDGF treatment, reflecting the requirement of SRF function for
PDGF-dependent cell proliferation (Figure 4B). The selective
response of FPCs to PDGF may partially explain the phenotypic
interactions observed between Srf and Pdgfra conditional mu-
tants but not Srf and Fgfr1 conditional mutants. Finally, we per-
formed scratch assays to compare the response of control and
Srf mutant FPCs. In Wnt1-Cre2; Srf+/fl FPCs, 10% fetal bovine
serum (FBS), PDGF, and FGF all induced significant wound
closure, but this response was abrogated under all conditions
in Wnt1-Cre2, Srffl/fl mutant FPCs, reflecting an intrinsic defect
in Srf mutant cells (Figure 4C; Figure S3D). Knockdown of SRF
is crucial for both cell motility and directional persistence (Medj-
kane et al., 2009); therefore, we performed time-lapse micro-
scopy and single cell tracking to better understand this deficit.
These experiments revealed that, although a subset of Wnt1-
Cre2; Srffl/fl mutant FPCs do move efficiently (Figure 4D; Fig-
ure S3E), Srf mutant FPCs, overall, are significantly slower and
exhibit decreased directional persistence compared to control
cells (Figure 4E). In summary, Wnt1-Cre2; Srffl/fl FPCs display
proliferation and motility defects in response to growth factor
stimulation, linking the observed in vivo proliferation and lineage
tracing defects in Srf mutants to RTK signaling and demon-
strating the functional relationship between these pathways in
the midface.
PDGF Mediates MRTFA-SRF Complex Formation
and Activates a Set of MRTF-SRF-Associated
Cytoskeletal Genes
In addition to direct transcriptional induction, many mechanisms
have been described to regulate SRF function, including alterna-
tive splicing (Belaguli et al., 1999), direct nuclear translocation
(Camoretti-Mercado et al., 2000), and differential cofactor usage
(Posern and Treisman, 2006). Therefore, we investigated howntal Cell 31, 332–344, November 10, 2014 ª2014 Elsevier Inc. 335
Figure 4. Srf Mutant E11.5 FPCs Do Not Proliferate in Response to PDGF and Exhibit Defective Wound Healing
(A) Srf mutant FPCs lack actin stress fibers, show decreased total F-actin staining, and display gross microtubule disorganization (n > 100 cells per condition).
(B) Control FPCs exhibit a modest proliferative response to PDGF stimulation, but Srf mutant FPCs fail to proliferate in response to PDGF (n = 4). BrdU,
bromodeoxyuridine.
(C) Although control FPCs show significant wound healing when treated with 10% FBS, PDGF, or FGF compared to 0.1% FBS, Srf mutant FPCs fail to show
significant closure when compared to 0.1% FBS starved cells (n = 3). Furthermore, Srf mutant FPCs show significant decreases in wound healing across all
growth factor conditions when compared to control FPCs.
(D) Representative trajectories from ten cells tracked during wound healing in response to either 10% FBS or PDGF. Srf mutant FPCs show both decreased
directionality and total distance traveled, although some mutant cells move relatively efficiently (blue trajectory in 10% FBS condition). The heterogeneous
migration properties were not due to incomplete loss of SRF (Figures S3B and S3C).
(E) Srfmutant cells show decreased speed and persistence in response to both 10% FBS and PDGF when compared to control cells (quartile plot with whiskers
spanning 5%–95%).
Scale bars, 25 mm. Data in (A)–(C) plotted as mean ± SEM. *p < 0.05; **p < 0.001; ^p < 0.001. Cells were treated with either 30 ng/ml PDGFAA or 50 ng/ml FGF1 +
1 mg/ml heparin.
See also Figure S3.
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signal specificity was encoded through these mechanisms. We
did not detect alternative splicing of SRF (Figures S4A–S4C),
and PDGF treatment did not significantly alter the cellular local-
ization of SRF in MEPMs (Figure S4D). Similarly, we did not
observe changes in SRF splicing or localization following FGF
treatment (data not shown), suggesting these mechanisms are
not utilized by either RTK in this context.
The two major cofactor families utilized by SRF are the TCFs
(Elk1, Elk3/Net, and Elk4/Sap1) and MRTFs (MRTFA/Mkl1
and MRTFB/Mkl2). MRTF-dependent SRF activity occurs
downstream of changes in actin concentration predominantly
mediated by Rho-family small GTPases (Miralles et al., 2003;336 Developmental Cell 31, 332–344, November 10, 2014 ª2014 ElsVartiainen et al., 2007). In contrast, TCF-dependent SRF activa-
tion lies downstream of ERK signaling (Posern and Treisman,
2006). The distinction between the two mechanisms of SRF
activation has a functional consequence, as unique SRF-regu-
lated gene sets are controlled through each of these pathways
(Gineitis and Treisman, 2001). Although RTK signaling is tradi-
tionally associated with robust activation of ERK, PDGF and
FGF have also been shown to modulate small GTPase function
in many contexts, including the midface (He and Soriano,
2013). We began by screening the expression of SRF cofactor
genes in MEPM RNA-seq and published E13.5 palate RNA-seq
data (http://www.facebase.org; FaceBase accession number
FB00000278.2); only Elk1, Elk3, and Mrtfa are expressed aboveevier Inc.
Figure 5. Both MRTF and TCF Cofactors
Play Roles Downstream of RTK Signaling
in Craniofacial Development
(A) Of the fivemajor TCF andMRTF cofactor family
members, only Elk1, Elk3, andMrtfa are expressed
above a threshold of ten FPKM in both E13.5
MEPMs and E13.5 palate.
(B) WISH reveals that Elk1 and Elk3 mRNA are
enriched in the E11.5 MNP. Mrtfa mRNA expres-
sion in the midface is more diffuse but shares
expression domains with Pdgfra and Srf.
(C) PDGF modestly increases SRF-MRTFA asso-
ciation while FGF reduces SRF-MRTFA complex
formation. MRTFA levels are not modulated
by PDGF or FGF treatment, thus serving as an
additional loading control.
(D) MRTFA-SRF association following 30 min
PDGF stimulation requires PI3K activity. All bio-
chemistry performed in E13.5 MEPMs. CD, cyto-
chalasin D; PD, PD325901; LY, LY294002; U,
untreated cells; P, 30 min 30 ng/ml PDGFAA; F,
30 min 50 ng/ml FGF1 + 1 mg/ml heparin.
(E) MRTFA immunofluorescence shows greater
nuclear accumulation of MRTFA in response to
PDGF compared to FGF, although a significant
number of FGF-treated cells contain nuclear
MRTFA. Red arrowheads mark cells counted as
containing nuclear MRTFA. Cytochalasin D and
latrunculin B were used as a positive and a
negative control, respectively. **p < 0.05.
Data plotted as mean ± SEM. See also Figure S4.
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million mapped reads (FPKM) in both data sets (Figure 5A). We
next performed WISH in E11.5 embryos to determine the ex-
pression pattern of these cofactors and compared them to Srf
and Pdgfra. Both Elk1 and Elk3 show strong expression in the
MNP, but Mrtfa is also expressed throughout the craniofacial
region, albeit more diffusely (Figure 5B). Thus, based on expres-
sion pattern alone, any of these cofactors may synergize with
SRF in the midface.
In order to directly test SRF-cofactor complex formation, we
treated E13.5 MEPMs with either PDGF or FGF, performed
immunoprecipitation (IP) for either Elk1 or MRTFA, and then
western blotted for SRF. Although both PDGF and FGF pro-
moted formation of an SRF-Elk1 complex, only PDGF treatment
resulted in SRF-MRTFA association; conversely, FGF stimula-
tion reduced the amount of SRF-MRTFA complex (Figure 5C;
Figure S4E). This PDGF-mediated SRF-MRTFA association
required PI3K (Figure 5D) activity, while SRF-Elk1 association
required both ERK and PI3K signaling (Figure S4E), consistent
with previous work implicating PI3K as the key effector of
PDGFRa signaling during craniofacial development (Klinghoffer
et al., 2002; Fantauzzo and Soriano, 2014). Since MRTF activa-
tion results in shuttling of the protein from the cytoplasm to the
nucleus (Miralles et al., 2003), we next performed MRTFA immu-
nofluorescence in MEPMs (Figure 5E). While MRTFA is predom-
inantly cytoplasmic in starved cells, PDGF stimulation increases
nuclear MRTFA. FGF also induces MRTFA translocation, but to
a lesser extent than PDGF. Indeed, PDGF-induced MRTFA
shuttling occurs at ratios comparable to those of cytochalasin-
D-treated MEPMs, consistent with a full MRTFA response to
PDGF. The observed heterogeneity of the MRTFA response inDevelopmeMEPMs may be, in part, a result of our primary cell culture sys-
tem, and quantitatively similar changes in nuclear MRTFA have
been observed in other studies (Ho et al., 2013).
These results raised the possibility that PDGF signaling prefer-
entially drives MRTFA-dependent SRF activity, while both PDGF
and FGF activate Elk1-mediated SRF function. In order to gain
insight toward the genome-wide role of SRF downstream of
these pathways, we integrated our MEPM RNA-seq data with
SRF chromatin immunoprecipitation sequencing (ChIP-seq)
data from mouse C2C12 (ENCODE Project Consortium, 2012;
GEO accession number GSM915168) and 3T3 (Esnault et al.,
2014) cells. Although SRF binding events are unlikely to be fully
conserved across different contexts, a previous study estimated
that 60% of SRF binding events in the proximal promoter are
shared between cell types (Sullivan et al., 2011), supporting
our correlative approach. We also recently generated an analo-
gous RNA-seq data set for FGF-treated MEPMs, allowing com-
parison of the transcriptional outputs from both PDGF and FGF
signaling (Table S2). First, we plotted the distribution of SRF
ChIP-seq peaks from the transcriptional start site (TSS) of all
genes upregulated at 1 hr by either PDGF (125 significant genes)
or FGF (135 significant genes) (Figures 6A and 6B). We found
enrichment of SRF ChIP-seq peaks upstream from the TSS of
RTK regulated genes, suggesting that SRF-mediated transcrip-
tion plays a key role in the genome-wide response to both
PDGF and FGF. A full list of these peaks and genes is provided
(Table S3). No such enrichment was observed in randomly
selected, expression-matched control genes (Figures 6A and
6B, black lines) unresponsive to growth factor treatment or
when plotting the peak distribution from ChIP-seq data for Jun
(induced on PDGF treatment in MEPMs), Pax5 (not expressedntal Cell 31, 332–344, November 10, 2014 ª2014 Elsevier Inc. 337
Figure 6. Both PDGF- and FGF-Responsive Genes Correlate with SRF Binding Genome-wide, but Only PDGF Target Gene Promoters
Are Enriched for MRTF
(A and B) Both PDGF (red) and FGF (blue) responsive genes show enrichment for SRF binding events from C2C12 (ENCODE Project Consortium, 2012) and
3T3 (Esnault et al., 2014) SRF ChIP-seq data. Randomly sampled expression matched control genes (black, n = 3 random sets) show no such enrichment.
A total of 67 PDGF responsive genes have an SRF ChIP-seq peak within 10 kb of the TSS, while 52 FGF-responsive genes have an SRF ChIP-seq peak within
10 kb of the TSS. *p < 0.1; **p < 0.05; ***p < 0.01.
(C) Closer inspection of SRF target genes downstream of each RTK reveals 56% overlap, with many classic IEGs (Fos, Jun, Egr) activated jointly by both PDGF
and FGF.
(D) PDGF-SRF targets show enrichment for actin cytoskeletal elements, while FGF-SRF targets show minimal functional organization.
(E) PDGF-SRF targets show significantly increased MRTF scores compared to FGF-SRF targets, consistent with PDGF-specific activation of an MRTF-
associated transcriptional program.
(F) SRF and MRTFA ChIP-qPCR in E13.5 MEPMs reveals increased binding of these factors at the promoters of cytoskeletal genes in response to PDGF (red)
in contrast to FGF (blue). Inhibition of PI3K signaling (patterned bars) reduces PDGF-stimulated SRF binding, although a significant response is still observed
at some promoters. *p < 0.1; **p < 0.05, compared to serum starved. (n = 3).
Cells were treated with 30 ng/ml PDGFAA or 50 ng/ml FGF1 + 1 mg/ml heparin. See also Figure S5 and Table S3.
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E13.5 palate) (Figures S5A–S5C).
A total of 94 PDGF and 95 FGF target genes contain an SRF
ChIP-seq peak within 70 kb of the TSS in either C2C12 or 3T3
cells; over half of these genes are induced by both pathways
(56% shared) (Figure 6C). Many classic IEGs (such as Fos,
Jun, and Egr) fall into the group of 53 genes with SRF binding
events that are jointly induced by both PDGF and FGF signaling.
Notably, a high percentage of genes (56%–75%) was conserved338 Developmental Cell 31, 332–344, November 10, 2014 ª2014 Elsin both ChIP-seq data sets (Table S3). Gene ontology analysis
revealed that PDGF-responsive SRF targets show overrepre-
sentation of genes associated with the actin cytoskeleton, while
FGF-mediated SRF targets show no such relationship (Fig-
ure 6D). To visualize these target genes at the level of cofactor
specificity, we next integrated our data sets with recently pub-
lished MRTF and TCF ChIP-seq data sets in 3T3 cells that
assigned a score for each target gene reflecting the relative
binding of these cofactors (Esnault et al., 2014) (Table S4). Weevier Inc.
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but a subset of PDGF-specific genes show high MRTF scores
(Figures S5D and S5E). Indeed, MRTF scores for PDGF-SRF
target genes are significantly increased compared to MRTF
scores or FGF-SRF target genes (Figure 6E), but no such differ-
ence is observed for TCF scores (Figure S5F). This correlation
between PDGF target genes and SRF-MRTF binding genome-
wide may reflect a PDGF-MRTF-SRF circuit not regulated by
FGF signaling.
SRFRegulates the Expression of aCytoskeletal Network
Critical for Craniofacial Development
Our genomic analyses suggest that PDGF-mediated SRF activa-
tion results in activation of a key cytoskeletal transcriptional pro-
gram; however, given that the ChIP-seq and RNA-seq data were
generated from different cell types, our correlative approach
alone does not delineate whether these binding events and
gene expression changes are functional. Thus, we probed this
network in more detail, using a candidate-based approach. We
selected eight genes for further study based on publishedmouse
craniofacial phenotypes and reported disease associations in
humans (Figure S6A). Many of these genes show high MRTF
scores and, in the case of Acta1 andMyh9, have been previously
identified as MRTF target genes (Sun et al., 2006; Medjkane
et al., 2009). We performed endogenous SRF ChIP in E13.5
MEPMs at previously identified SRF binding sites in these eight
target promoters, finding six (Vcl, Acta2, Myh9, Actb, Tgln,
Flna) to show SRF binding (Figure S6B). Five of these six pro-
moters (Acta2, Vcl, Myh9, Actb, Flna) exhibit increased SRF
binding following PDGF stimulation; comparing the two RTKs,
all six targets show significantly greater SRF binding in response
to PDGF, while only one promoter (Actb) exhibits increased
binding following FGF stimulation (Figure 6F). In contrast, SRF
binding at the promoter of the shared target Fos is induced
by both PDGF and FGF signaling, and low occupancy was
observed in the promoter of Arid5b, an IEG not bound by SRF
in either ChIP-seq data set (Figure S6C).
Given the importance of PI3K signaling downstream of PDGF
in the midface, we assayed the effect of PI3K inhibition on SRF
binding. We found decreased PDGF-mediated SRF binding at
all six targets following pretreatment with LY294002; however,
two target promoters (Acta2 and Actb) still showed significant
responses, indicating that PI3K signaling is not always required
for SRF binding (Figure 6F). In addition, PI3K inhibition signifi-
cantly decreased SRF binding at the Tagln promoter across all
conditions, suggesting that PI3K promotes SRF maintenance
at this locus. Next, we carried out endogenous MRTFA ChIP
and demonstrate significantly increased MRTFA binding at four
loci (Acta2, Vcl, Myh9, Actb) in response to PDGF treatment
(Figure 6F). In contrast, FGF induced significant MRTFA binding
at only the Actb promoter, consistent with the increased SRF
binding at this region. No MRTFA binding was observed at either
the Flna or the Fos (Figure S6C) promoter. Collectively, these
results indicate that PDGF and FGF differentially modulate SRF
and MRTFA binding at target gene promoters, in part through
PI3K signaling.
To determine the MRTF dependence of these genes, we stim-
ulatedMEPMswith PDGF or FGF in the presence of latrunculin B
(Figure 7A). All six genes are selectively induced by PDGF.DevelopmeFurthermore, latrunculin B inhibits the PDGF-mediated expres-
sion of five genes (Acta2, Vcl, Myh9, Actb, Tagln), confirming
that these targets are indeed MRTF dependent. While MRTFA
nuclear accumulation is observed at 30 min following PDGF
treatment, both the repressive effect of latrunculin B and
observed MRTFA binding at target gene promoters is more pro-
nounced at 4 hr, suggesting that MRTF-mediated changes in
gene expression may be a delayed response. The induction of
Fos by both PDGF and FGF is not affected by latrunculin B (Fig-
ure S6D). We then measured the expression of these six genes
in E11.5 facial prominences (MNP, LNP, and MxP) dissected
from Srf, Pdgfra, and Fgfr1 conditional mutants. As expected,
the expression of Srf, Pdgfra, and Fgfr1 were decreased in the
corresponding mutants; furthermore, we observed downregula-
tion of all six targets in Srfmutant facial prominences (Figure 7B).
Finally, we found significantly decreased expression of four
PDGF-SRF targets (Vcl,Myh9,Actb, and Flna) inPdgframutants,
but not Fgfr1 mutants (Figure 7B). It is interesting that a modest
increase in Pdgfra expression was observed in Srf mutants,
possibly indicating a compensatory feedback mechanism.
These results reflect the perturbation of a PDGF-responsive,
MRTF-dependent cytoskeletal circuit specifically in Pdgfra and
Srf mutants.
Our data suggest the following model: PDGF mediates
MRTFA-SRF association and binding at select target gene pro-
moters to drive MRTF-dependent expression of key actomyosin
cytoskeleton elements (such as Vcl, Actb, Acta2, and Myh9).
In contrast, both PDGF and FGF signaling increase Elk1-SRF
complex formation to modulate the classic IEG signature
(including Fos, Fosb, and Junb) observed downstream of these
pathways. By building a protein-protein interaction (PPI) network
of the targets downstream of PDGF, FGF, and SRF (Chen et al.,
2012), we can better visualize this specificity at both the RTK
and cofactor levels (Figure 7C). Consistent with our framework,
the PDGF-specific PPI network shows strong correlation with
MRTF target genes. Our studies imply that loss of this PDGF-
MRTF-SRF axis explains, in part, both the craniofacial pheno-
types of Pdgfra and Srf conditional mutants and the observed
phenotypic interaction between these two genes.
DISCUSSION
SRF is a classic regulator of the transcriptional response to
growth factor signaling. In the present study, we find that neural
crest conditional loss of SRF results in facial clefting accompa-
nied by proliferation and migration defects. By analyzing SRF
activation downstream of both PDGF and FGF signaling, we
uncover a PDGF-MRTF-SRF circuit critical for cytoskeletal
gene expression in the midface. We conclude that SRF is
required for craniofacial development and that RTK signaling en-
codes the specificity of SRF-mediated gene expression at the
level of cofactor recruitment in this developmental context.
Many phenotypes have been reported in SRF neural crest
conditional mutants (Newbern et al., 2008, Wickramasinghe
et al., 2008), and we now describe gross facial clefting in these
mutants, which had not been previously appreciated. We further
demonstrate that SRF drives proliferation of the NCC-derived
MNP mesenchyme. MNP cell proliferation is also decreased in
Wnt1-Cre; Pdgfrafl/fl mice (He and Soriano, 2013), suggesting antal Cell 31, 332–344, November 10, 2014 ª2014 Elsevier Inc. 339
Figure 7. A PDGF-MRTF-SRF Axis Controls Expression of Key Cytoskeletal Regulators in Craniofacial Development
(A) PDGF (red bars) robustly activates expression of cytoskeletal target genes inMEPMs, while FGF (blue bars) does not. Latrunculin B treatment (patterned bars)
inhibits PDGF-mediated gene expression, indicating that induction of these shared PDGF-SRF targets is MRTF dependent.
(B) The expression of all six cytoskeletal SRF target genes is reduced in E11.5Wnt1-Cre; Srffl/flmutant facial prominences (gray bars). While none of these genes
show reduced expression in Wnt1-Cre; Fgfr1fl/fl mutant facial prominences (blue bars), four of six genes (Vcl, Myh9, Actb, and Flna) show downregulation in
Wnt1-Cre; Pdgfrafl/fl mutant facial prominences (red bars).
(C) PPI network constructed from PDGF-regulated SRF target genes (red) and FGF-regulated SRF target genes (purple) recapitulates unique SRF functions
downstream of PDGF signaling. Furthermore, the PDGF specific SRF network contains an enrichment of MRTF target genes (squares) compared to the
shared network, which has equal TCF (triangle), MRTF (square), and nonspecific (circles) genes. All six genes with altered expression in SRF mutants (bold) fall
under the PDGF-specific network, and many PDGF-SRF target genes have known roles in craniofacial development (sources: http://www.informatics.jax.org;
http://www.omim.org).
Data are plotted as mean ± SEM. *p < 0.1; **p < 0.05, compared to serum starved or wild-type control; ^^p < 0.05, compared to latrunculin B treatment (n = 3).
See also Figure S6 and Table S4.
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Consistent with this notion, SRF mutant FPCs fail to proliferate
in response to PDGF stimulation. Thus, PDGF signaling acts
through SRF to drive a functional proliferation program in the
midface. In the epidermis, loss of Srf leads to cell proliferation
defects due to abnormalities in the actomyosin network (Luxen-
burg et al., 2011); many targets of the PDGF-MRTF-SRF axis
elucidated in our study (such as Actb, Myh9, Flna, and Actg1)
were also implicated in the proliferation defects observed in
these epidermis-specific Srf mutants, reflecting the importance
of these genes. We further show that Wnt1-Cre; Srffl/fl embryos340 Developmental Cell 31, 332–344, November 10, 2014 ª2014 Elsexhibit lineage tracing defects characterized by decreased infil-
tration of NCCs into the FNP and first two branchial arches,
raising the possibility that the facial clefting may be, in part, the
result of an insufficient number of neural-crest-derived progeni-
tors populating the craniofacial mesenchyme. To understand the
basis for these deficits, we analyzed SRF-deficient primary cells
isolated from the cranial NCC-derived facial prominences and
demonstrated decreased speed and directional persistence in
wound healing assays. On delamination from the dorsal neural
tube, NCCs migrate in stereotypic streams throughout the em-
bryo to populate a diverse range of derivatives, responding toevier Inc.
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tions (Theveneau and Mayor, 2012). Many PDGF-regulated
SRF target genes in our study are involved in force generation
(Myh9, Myl6, Myl12b), focal adhesion formation (Vcl, Flna, Zyx),
and cytoskeletal organization (Actb, Actg1, Acta2), key pro-
cesses for cell migration. In addition, MRTFs have been shown
tomediate cell motility and directionality in other contexts (Medj-
kane et al., 2009), suggesting that the observed defects may be
MRTF dependent.
On activation, RTKs become phosphorylated and engage
downstream effectors, which, in turn, activate many shared
intracellular pathways. One outcome of this signaling cascade
is the transcription of IEGs. Many RTKs induce overlapping
sets of IEGs, leaving open the question of how transcriptional
specificity is generated. We demonstrate that PDGF, but not
FGF, selectively promotes recruitment of SRF and MRTFA to
target gene promoters, leading to induction of a unique gene
expression program. This PDGF-MRTF-SRF axis is enriched
for cytoskeletal regulators, many of which exhibit MRTF-
dependent induction and decreased expression in Srf and
Pdgfra mutants. On the other hand, both PDGF and FGF
increase Elk1-SRF complex formation, in line with our obser-
vation that over half of the identified SRF target genes are
jointly activated by both PDGF and FGF. The targets down-
stream of this shared RTK-Elk1-SRF axis, such as Fos, Jun,
and Egr, constitute a classic set of IEGs activated by multiple
pathways (Fambrough et al., 1999), suggesting that other stim-
uli can compensate for loss of Elk1-SRF-mediated transcrip-
tion. Consistent with this notion, Srf null embryos express
residual amounts of Fos and Egr1 but show complete loss of
Acta1 expression (Arsenian et al., 1998). We propose that the
PDGF-MRTF-SRF axis has unique roles in the developing
midface, an assertion supported by our epistasis results and
gene expression studies.
Two critical points merit further discussion. First, what are the
key signaling parameters encoding differential cofactor activa-
tion and SRF-mediated gene expression downstream of PDGF
and FGF signaling? A potential answer lies in the importance
of PI3K activity in the formation of an MRTFA-SRF complex
and in driving maximal SRF binding at target gene promoters
in response to PDGF stimulation. Previous studies have shown
PI3K to be the primary effector downstream of PDGF signaling
during midface development, closely mirroring the craniofacial
phenotypes observed in PDGFRa mutants (Klinghoffer et al.,
2002; Fantauzzo and Soriano, 2014). Thus, one explanation
is that PDGF-activated PI3K signaling selectively promotes
MRTFA-SRF association, perhaps through Rho-family small
GTPases, which modulate actin dynamics and MRTF activity
in other contexts (Pipes et al., 2006). Both Rac1 and Cdc42
are required in the neural crest for craniofacial development
(Thomas et al., 2010; Fuchs et al., 2009) and have been
implicated downstream of PDGF signaling in MEPMs (He and
Soriano, 2013; Fantauzzo and Soriano, 2014). Although FGF
signaling can modulate both Rac1 and Cdc42 in other systems
(Fera et al., 2004; Clark et al., 2011), it is unclear whether this
relationship is conserved in the midface. Alternatively, while
both PDGF and FGF signal through common kinase cascades,
the magnitude and duration of this induction can be quite
different. Indeed, PDGF- and FGF-mediated pERK activationDevelopmepatterns are markedly different in MEPMs, with PDGF stimula-
tion resulting in a transient pERK pulse but FGF treatment driving
sustained pERK activation (unpublished data). Consistent with
this observation, a recent study showed that sporadic pERK
pulses drive SRF-mediated transcription more efficiently than
sustained pERK activity (Aoki et al., 2013), reflecting yet another
layer of control. In summary, a combination of both qualitative
and quantitative differences in signaling parameters likely ac-
counts for the observed SRF specificity.
Second, is this specificity of SRF activation ‘‘hard wired’’ into
the PDGF and FGF signaling networks, or is it context depen-
dent? The answer is almost certainly the latter, as the magni-
tude and kinetics of activation downstream of even the same
RTK can vary depending on many parameters, including
expression level (Traverse et al., 1994). The expression pattern
of many signaling components is restricted over the course of
development, necessitating diverse, context-specific control
systems. The neural crest itself is a multipotent population
with many sublineages, all expressing different combinations
and amounts of receptors and signaling effectors. In the case
of PDGFRa and SRF, we describe a PDGF-SRF circuit in the
midface. However, many of the observed hemorrhaging and
blistering phenotypes in these mutants may be due, in part, to
requirements for PDGF signaling and SRF activity in neural-
crest-derived vascular components, such as smooth muscle
cells and pericytes (Etchevers et al., 2001). The PDGF-SRF
signaling axis may be wired differently in these cells, particularly
at the levels of receptor activation, effector requirements, and
cofactor recruitment. In DRG sensory neurons, SRF activity
downstream of nerve growth factor is dependent on ERK-medi-
ated MRTFA activity, but not on TCF-SRF complex formation
(Wickramasinghe et al., 2008). Thus, SRF function can be
controlled by different RTKs in divergent neural crest lineages
through a common set of cofactors and signaling effectors.
The degree of sophistication and stimulus-dependent utilization
of SRF regulatory mechanisms is remarkable, and determining
the exact rules governing SRF activity following receptor activa-
tion across these diverse developmental contexts will be
rewarding. Our studies provide one such example of the intri-
cate control systems in place to encode transcriptional speci-
ficity downstream of two different RTKs at the level of SRF
cofactor recruitment.EXPERIMENTAL PROCEDURES
Mouse Strains
All animal experiments were approved by the Institutional Animal Care and
Use Committee at the Icahn School of Medicine at Mount Sinai. Srftm1Rmn
mice (Ramanan et al., 2005), referred to as Srffl/fl in the text, were a gift from
Dr. Xin Sun, University of Wisconsin-Madison, and were backcrossed a min-
imum of three generations to 129S4 mice prior to all experiments included in
this study. Tg(Wnt1-Cre)2Sor mice (Lewis et al., 2013), referred to as Wnt1-
Cre2 in the text, were backcrossed to 129S4 mice for four generations prior
to all experiments in this study. Pdgfratm11(EGFP)Sor (Hamilton et al., 2003),
referred to as PdgfraGFP/+ in the text, and Gt(ROSA)26Sortm1Sormice (Soriano,
1999), referred to as R26R in the text, were maintained on a C57BL/6 back-
ground. PDGFRatm8Sor mice (Tallquist and Soriano, 2003), referred to as
Pdgfrafl/fl, in the text, FGFR1tm5.1Sor mice (Hoch and Soriano, 2006), referred
to as Fgfr1fl/fl in the text, and Tg(Wnt1-Cre)11Rth mice (Danielian et al.,
1998), referred to as Wnt1-Cre in the text, were all maintained on a 129S4
genetic background.ntal Cell 31, 332–344, November 10, 2014 ª2014 Elsevier Inc. 341
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Primary MEPM cells were isolated from E13.5 secondary palatal shelves
(day of plug: E0.5) as previously described (Fantauzzo and Soriano, 2014).
Primary mouse FPCs were generated from E11.5 mouse facial prominences
(Figure S3B), but we were unable to passage these FPCs in culture. Therefore,
MEPMswere used for further experiments investigating RTK-mediated control
of SRF function, such as western blots and ChIP. For proliferation assays, cells
were starved overnight and then incubated with 10 mm bromodeoxyuridine
for 4 hr (Bush and Soriano, 2010) with either 30 ng/ml PDGFAA or 50 ng/ml
FGF1 + 1 mg/ml heparin. For wound healing assays, cells were grown to con-
fluence, starved overnight, and then scratched. Details are available in the
Supplemental Experimental Procedures.
Histology, In Situ Hybridization, and Immunofluorescence
Embryos were dissected and embedded in either paraffin or optimal cutting
temperature compound for sectioning. In situ hybridization and immuno-
fluorescence were performed according to standard protocols. See the
Supplemental Experimental Procedures for further details.
qPCR
For analysis of SRF induction, E13.5 MEPMs were starved overnight and then
treated with PDGF or FGF for the desired time duration. For analysis of SRF
target gene expression in mutant embryos, E11.5 facial prominence lysates
were harvested, and RNA was extracted directly from tissue. All experiments
were conducted on litters from three independent biological replicates. Statis-
tical analysis was performed using a two-tailed, paired Student’s t test for
MEPM time courses, in which cells from the same embryo were considered
paired. For comparison of expression between facial prominence lysates
from different genotypes, a two-tailed, unpaired Student’s t test was used.
Further details are available in the Supplemental Experimental Procedures.
Time-Lapse Imaging
FPCs were prepared and scratch assays performed as described earlier. Live
cell imaging was carried out on an Olympus IX-70 wide-field epifluorescence
system with a stage-top incubation chamber to maintain cell viability. Images
were taken with a 103 lens every 5min across 250min, for a total of 50 images
per field of view. Four fields of view per condition per embryo were imaged,
and two independently dissected control and mutant embryos were analyzed.
Ten cells were randomly selected in each field of view for tracking and calcu-
lation of migration parameters; thus, a total of 40 cells per condition per
embryo were analyzed. Image analysis was performed in ImageJ (v 1.47;
NIH) using the Manual Tracking plugin. Calculation of trajectories, speed,
and persistence were implemented through custom code in R (http://www.
R-project.org/) (R Core Team, 2013).
IP and Western Blot
E13.5 MEPMs were serum starved for 24 hr in 0.1% FBS and stimulated with
PDGF or FGF for desired duration. When applicable, cells were pretreated for
1 hr with 10 mM of desired inhibitor. IPs and western blots were performed ac-
cording to standard protocols using horseradish-peroxidase-conjugated sec-
ondary antibodies and quantified in ImageJ (v 1.47; NIH). A minimum of two
biological replicates were performed for each set of IP experiments. Further
details are provided in the Supplemental Experimental Procedures.
ChIP
E13.5 MEPMs were isolated and stimulated with PDGF or FGF as described
earlier. ChIP was performed as previously described (Fantauzzo and Soriano,
2014) to test occupancy in input, immunoglobulin G, and antibody (anti-SRF or
anti-MRTFA)-precipitated samples. qPCR was carried out as described
earlier, and statistics were performed using a two-tailed, paired Student’s
t test, in which cells from the same embryo were considered paired. Data
presented are from three independent biological replicates. Further details
are provided in the Supplemental Experimental Procedures.
ChIP-Seq and RNA-Seq Data Integration
C2C12 SRF ChIP-seq peak data were downloaded directly from the ENCODE
Project Consortium (http://www.encodeproject.org; GEO accession number:
GSM915168) in the ‘‘narrowPeaks’’ format, which lists significant peaks iden-342 Developmental Cell 31, 332–344, November 10, 2014 ª2014 Elstified by the ENCODE Project Consortium. 3T3 SRF ChIP-seq data were simi-
larly obtained (Esnault et al., 2014). Chromosomal coordinates for each of
these peaks were then compared to the TSS for each gene regulated by
PDGF or FGF signaling at 1 hr, and a frequency distribution was generated
by counting the number of peaks within successive 10 kb bins of the TSS.
Strategy was implemented through custom code in R. Similar distributions
for control gene sets (randomly selected, expression-matched genes that
are not regulated by RTK activation) were generated to assess baseline
ChIP-seq peak enrichment. A similar approach was implemented for the
following control ChIP-seq data sets:
(1) Jun (GEO accession number GSM9212901);
(2) Pax5 (GEO accession number GSM923584); and
(3) E13.5 palate p300 (http://www.facebase.org; FaceBase accession
number FB00000263).
ACCESSION NUMBERS
The GEO accession number for the MEPM RNA-seq data reported in this
paper is GSE61755.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.devcel.2014.10.005.
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